Report Overview

Global Liquid Biopsy Market - Industry Trends & Forecast Report 2028

Global Liquid Biopsy Market was worth USD 2.67 billion in 2021 and is further projected to reach USD 9.30 billion by the year 2028, exhibiting a CAGR of 19.7% during the forecast period (2022-2028). The rapid expansion of the market is predominantly due to a rise in the number of cancer patients, improvements in patient desire for minimally invasive therapy, and the use of next-generation sequencing for cancer patients in liquid biopsies. Moreover, the market growth rate is being pushed by the surge in demand for better diagnosis equipment and the expansion of research labs in developing nations. Additionally, the prevalence of blood cancer is rising globally, which is paving the way for market expansion. Furthermore, rising R&D spending, particularly in developed and developing economies, is expected to create more lucrative market growth opportunities for medical instruments and devices. The research and development capabilities of pharmaceutical and biopharmaceutical countries for the integration of advanced technologies in healthcare facilities are also boosting market growth rates.

Liquid Biopsy - Overview

A blood test that looks for cancer cells from a tumor that are circulating in the blood or DNA fragments from tumor cells that are in the blood. A liquid biopsy could aid in the early detection of cancer. The name implies that liquid biopsy is a non-invasive and quick technology that uses a sample to perform a blood test. Liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is used to diagnose cancer cells that form tumors and circulate in the bloodstream. Liquid biopsy is used in the early detection and diagnosis of cancer. The benefits of liquid biopsy include that it is non-invasive, quick, accurate, and especially real-time. Additionally, it can get around tumor heterogeneity and could eventually take the place of tissue biopsy.

Global Liquid Biopsy Market Forecast and Trends

Growth Drivers

Increasing Cancer Incidence and Prevalence

The number of persons who have cancer has significantly increased on a global scale. Environmental factors, cigarette use, infectious diseases like Hepatitis B and C, as well as lifestyle changes, are some of the causes of the increased incidence of cancer. Cancer is the second-leading cause of mortality worldwide, according to the WHO. According to estimates from the International Agency for Research on Cancer (IARC), there would be 19.3 million new cases of cancer and 9.96 million cancer-related deaths worldwide in 2020. Compared to conventional cancer diagnostic methods, liquid biopsy has various advantages, including lower cost, early prognosis, therapy monitoring, tumor heterogeneity identification, acquired drug resistance, and patient comfort (by eliminating the need for surgery). Consequently, the preference for liquid biopsies is anticipated to increase during the projection period in line with the rise in cancer prevalence.

Investments by the Government in Healthcare Infrastructure

The federal government's increased funding is expected to drive the market's growth rate. Furthermore, the growth and expansion of the healthcare industry, driven by both public and private players, will create lucrative market growth opportunities, particularly in developing economies. Furthermore, the high return on investment guaranteed by research activities will benefit the market. Furthermore, government initiatives to raise awareness, particularly in developing economies, an increase in personal disposable income, the introduction of technologically-driven products in hospitals, increased investment in the development of advanced medical products and devices, and an increase in demand for non-invasive surgical procedures all have a positive impact on the market growth rate.

Companion Diagnostics' Expanding Importance

Companion diagnostics are tests or assays used to help doctors decide what course of treatment to provide patients based on how well they respond to therapy. The rapid and cost-effective production of safer pharmaceuticals with improved therapeutic efficacy can fundamentally modify the drug development process and accelerate the commercialization of medication candidates. The market for companion diagnostics has significant growth potential as a result of the rise in demand for expensive specialized therapies and safer medications. The market for liquid biopsies is seeing prospects for expansion as companion diagnostics gain in prominence.

Restraints

High Research and Development Costs

The factors like high research and development costs, a lack of adequate infrastructure, and the lesser sensitivity of some liquid biopsies will limit market expansion. In addition, in the forecast period of 2022–2028, low sensitivity and specificity limitations of liquid biopsy, an absence of adequate infrastructure in low- and middle-income countries, and an unfavorable reimbursement scenario and technology penetration in developing economies are anticipated to pose challenges to the market. All these factors restrain the growth of the Global Liquid Biopsy Market.

Impact of COVID-19 on Global Liquid Biopsy Market

Although COVID-19's far-reaching consequences have been unprecedented, cancer sufferers have been among the most severely impacted groups. The number of patients getting cancer screening, diagnosis, and treatment has been significantly impacted by COVID-19. Oncology clinics were re-profiled for treating patients with COVID-19 as a result of the increasing demand brought on by the rising rate of COVID-19 patients being hospitalized. As a result, a study found that numerous diagnostic and therapeutic operations, including up to 2.3 million cancer surgeries, have been shelved or delayed globally.

However, as nations gradually loosen their travel restrictions, testing numbers are expected to increase again. Responding to rising cancer incidence has become a critical medical concern on a global scale since the COVID-19 pandemic. Cancer has been recognized as a risk factor for COVID-19 because several COVID-19 patients had malignancies. It is predicted that additional research in this area would advance cancer research by helping to better understand the dynamics of infection. It is also anticipated that this will increase demand for liquid biopsy products.

Global Liquid Biopsy Market - By Sampling Type

Based on the sampling type, the Global Liquid Biopsy Market is segmented into Blood Sampling, Urine Sampling, Saliva Sampling, and Other Tissue Fluids Sampling. Among these, blood sampling accounts for the largest share of the Global Liquid Biopsy Market.  Blood is the most commonly used sample type and is expected to continue to be the largest market during the forecasting period. Moreover, the urine sampling segment is expected to grow significantly over the forecast period. Although still in the early stages when compared to blood-based liquid biopsy, recent studies have shown the value of urine-based liquid biopsies for nonurological cancer screening, early detection, monitoring for recurrence and metastasis, and therapeutic efficacy. Overall, the urine-based biopsy's completely noninvasive and patient-friendly nature warrants further development and offers a promising alternative to blood-based biopsies.

Global Liquid Biopsy Market – By Product and Service

Based on product and service, the Global Liquid Biopsy Market is segmented into Assay Kits, Instruments, and Services. Among these, the assay kits segment holds the largest market share. Assay kits are a recurring cost due to their standard purchase requirement, which is a key factor contributing to the growth of this segment. In 2020, the assay kits category hold the greatest market share. Assay kits typically need to be purchased, making them a recurring expense, which is a major driver of this market's expansion. There are several applications for assay kits in life science research, drug discovery & development, and environmental monitoring, including analyzing biopharmaceutical manufacturing procedures, examining disease pathways, and finding viable drug candidates. All these factors boost the growth of the Global Liquid Biopsy Market during the forecast period (2022-2028).

Global Liquid Biopsy Market - By Application

Based on application, the Global Liquid Biopsy Market is segmented into Cancer Applications and Non-Cancer Applications. Among these, cancer applications dominate the market share. The expansion of this market is being driven by elements like the rising incidence of cancer and the rise in research studies on liquid biopsy for cancer applications. The market is further divided into cancer types such as lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and others. Because of the global increase in the prevalence of non-small cell lung cancer, the lung cancer segment is expected to dominate the liquid biopsy market. According to the World Health Organization, lung cancer is by far the leading cause of cancer death in both men and women, with an estimated 1.80 million deaths worldwide in 2020. Furthermore, as the most common type of cancer and the second leading cause of death in North America, prostate cancer is expected to be the fastest-growing segment during the forecast period.

Global Liquid Biopsy Market - By End-User

Based on end-user, the Global Liquid Biopsy Market is segmented into Reference Laboratories, Hospitals, Physician Laboratories, Academic Researchers, and Others. Among these, hospitals dominate the market share owing to the increased use of liquid biopsy tests in hospitals and laboratory settings, which are preferred healthcare facilities for patients. Also, rising cancer incidence and prevalence, as well as a growing preference for non-invasive treatment procedures influence the hospital segment to dominate the market share.

Global Liquid Biopsy Market - By Region

Geographically, the Global Liquid Biopsy Market is segmented into North America, Europe, The Asia Pacific, Latin America, and The Middle East and Africa. North America dominates the market owing to the presence of large key players such as Biocept, F. Hoffmann-La Roche AG, Qiagen N.V., and others. Furthermore, the high cancer prevalence and widespread adoption of novel liquid biopsy tests contribute to the growth of the North American liquid biopsy market. During the analysis period, Asia-Pacific is expected to have the highest CAGR. This is due to an increase in disposable income, government initiatives to modernize healthcare infrastructure, and an increase in healthcare expenditure. Furthermore, strategic approvals and collaborations between leading market players to promote liquid biopsy technology in this region are expected to increase.

Competitive Landscape

The leading market players in the Global Liquid Biopsy Market are F. Hoffmann-La Roche Ltd, Myraid Genetics, QIAGEN, Thermo Fisher Scientific Inc, Guardant Health, MDxHealth SA, Exact Sciences Corporation, Sysmex Inostics, Bio-Rad Laboratories, ANGLE plc, and other prominent players.

The Global Liquid Biopsy Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Recent Developments

• In June 2021, Guardant Health, Inc. (US) launched its Guardant360 Response test that detects changes in circulating tumor DNA (ctDNA) levels.

• In October 2020, F. Hoffmann-La Roche Ltd. (Switzerland) received the US FDA approval of expanded claims for the cobas EGFR Mutation Test v2 to be used as a companion diagnostic (CDx) for a broader group of therapies to treat non-small cell lung cancer (NSCLC).

• In September 2020, Personalis, Inc. launched NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients.

 Scope of the Report

By Sampling Type

• Blood Sampling

• Urine Sampling

• Saliva Sampling

• Other Tissue Fluids Sampling

By Product and Service

• Assay Kits

• Instruments

• Services

By Circulating Biomarker

• Circulating Tumor Cells

• Circulating Tumor DNA

By Clinical Application

• Early Cancer Screening

• Therapy Selection

• Treatment Monitoring

• Recurrence Monitoring

By Application

• Cancer Applications

• Non-Cancer Applications

By End User

• Reference Laboratories

• Hospitals

• Physician Laboratories

• Academic Researchers

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
3. Executive Summary
4. Global Liquid Biopsy Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Advancement/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
5. Global Liquid Biopsy Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Sampling Type
         1. Blood Sampling
         2. Urine Sampling
         3. Saliva Sampling
         4. Other Tissue Fluids Sampling
      2. By Product and Service
         1. Assay Kits
         2. Instruments
         3. Services
      3. By Circulating Biomarker
         1. Circulating Tumor Cells
         2. Circulating Tumor DNA
      4. By Clinical Application
         1. Early Cancer Screening
         2. Therapy Selection
         3. Treatment Monitoring
         4. Recurrence Monitoring
      5. By Application
         1. Cancer Applications
         2. Non-Cancer Applications
      6. By End User
         1. Reference Laboratories
         2. Hospitals
         3. Physician Laboratories
         4. Academic Researchers
         5. Others
      7. By Region
         1. North America
         2. Europe
         3. The Asia Pacific
         4. Latin America
         5. The Middle East and Africa
6. North America Liquid Biopsy Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Sampling Type
      2. By Product and Service
      3. By Circulating Biomarker
      4. By Application
      5. By Clinical Application
      6. By End User
      7. By Country
         1. United States
         2. Canada
7. Europe Liquid Biopsy Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Sampling Type
      2. By Product and Service
      3. By Circulating Biomarker
      4. By Application
      5. By Clinical Application
      6. By End User
      7. By Country
         1. Germany
         2. United Kingdom
         3. Italy
         4. France
         5. Spain
         6. Rest of Europe
8. The Asia Pacific Liquid Biopsy Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Sampling Type
      2. By Product and Service
      3. By Circulating Biomarker
      4. By Application
      5. By Clinical Application
      6. By End User
      7. By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Rest of Asia Pacific
9. Latin America Liquid Biopsy Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Sampling Type
      2. By Product and Service
      3. By Circulating Biomarker
      4. By Application
      5. By Clinical Application
      6. By End User
      7. By Country
         1. Brazil
         2. Mexico
         3. Rest of Latin America
10. The Middle East & Africa Liquid Biopsy Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Sampling Type
       2. By Product and Service
       3. By Circulating Biomarker
       4. By Application
       5. By Clinical Application
       6. By End User
       7. By Country
          1. Saudi Arabia
          2. UAE
          3. South Africa
          4. Rest of Middle East & Africa
11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Merger, Acquisition, Partnership, etc.)
12. Impact of Covid-19 on Global Liquid Biopsy Industry
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. F. Hoffmann-La Roche Ltd
    2. Myraid Genetics
    3. QIAGEN
    4. Thermo Fisher Scientific Inc
    5. Guardant Health
    6. MDxHealth SA
    7. Exact Sciences Corporation
    8. Sysmex Inostics
    9. Bio-Rad Laboratories
    10. ANGLE plc
    11. Other Prominent Players
14. Key Strategic Recommendations

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

Figure 1: Global Liquid Biopsy Market Segmentation

Figure 2: Global Liquid Biopsy Industry Value Chain Analysis

Figure 3: Global Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 4: Global Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 5: Global Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 6: Global Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 7: Global Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 8: Global Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 9: Global Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 10: Global Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028

Figure 11: North America Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 12: North America Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 13: North America Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 14: North America Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 15: North America Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 16: North America Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 17: North America Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 18: North America Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028 

Figure 19: Europe Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 20: Europe Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 21: Europe Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 22: Europe Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 23: Europe Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 24: Europe Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 25: Europe Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 26: Europe Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028

Figure 27: The Asia-Pacific Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 28: The Asia-Pacific Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 29: Asia-Pacific Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 30: Asia-Pacific Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 31: The Asia-Pacific Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 32: The Asia-Pacific Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 33: The Asia-Pacific Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 34: The Asia-Pacific Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028

Figure 35: Latin America Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 36: Latin America Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 37: Europe Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 38: Europe Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 39: Latin America Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 40: Latin America Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 41: Latin America Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 42: Latin America Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028

Figure 43: The Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2018-2028

Figure 44: The Middle East & Africa Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028

Figure 45: The Middle East & Africa Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028

Figure 46: The Middle East & Africa Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028

Figure 47: The Middle East & Africa Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028

Figure 48: The Middle East & Africa Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028

Figure 49: The Middle East & Africa Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028

Figure 50: The Middle East & Africa Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028

Figure 51: Global Liquid Biopsy Market Share Analysis, 2021

List of Tables

Table 1: Global Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 2: Global Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 3: Global Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028

Table 4: Global Liquid Biopsy Market Size, By Application, By Value (USD Million), 2018-2028

Table 5: Global Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 6: Global Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 7: Global Liquid Biopsy Market Size. By Country, By Value (USD Million), 2018-2028

Table 8: North America Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 9: North America Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 10: North America Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028

Table 11: 28 North America Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028

Table 12: North America Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 13: North America Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 14: 28 North America Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028 

Table 15: Europe Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 16: Europe Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 17: Europe Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028

Table 18: 40 Europe Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028

Table 19: Europe Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 20: Europe Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 21: 40 Europe Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028

Table 22: The Asia-Pacific Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 23: The Asia-Pacific Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 24: The Asia-Pacific Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028

Table 25: The Asia-Pacific Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028

Table 26: The Asia-Pacific Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 27: The Asia-Pacific Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 28: The Asia-Pacific Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028

Table 29: Latin America Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 30: Latin America Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 31: Latin America Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028

Table 32: Latin America Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028

Table 33: Latin America Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 34: Latin America Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 35: Latin America Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028

Table 36: The Middle East & Africa Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028

Table 37: The Middle East & Africa Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028

Table 38: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Circulating Biomarker, By Value 2018-2028

Table 39: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028

Table 40: The Middle East & Africa Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028

Table 41: The Middle East & Africa Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028

Table 42: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028 

Table 43:  List of Key Players and Their Offerings

Table 44:  Competitive Benchmarking, by Operating Parameters

Table 45        F. Hoffmann-La Roche Ltd Company Overview

Table 46        F. Hoffmann-La Roche Ltd Financial Overview

Table 47        Myraid Genetics Company Overview

Table 48        Myraid Genetics Financial Overview

Table 49        QIAGEN Company Overview

Table 50        QIAGEN Financial Overview

Table 51        Thermo Fisher Scientific Inc Company Overview

Table 52        Thermo Fisher Scientific Inc Financial Overview

Table 53        Guardant Health Company Overview

Table 54        Guardant Health Financial Overview

Table 55        MDxHealth SA Company Overview

Table 56        MDxHealth SA Financial Overview

Table 57        Exact Sciences Corporation Company Overview

Table 58        Exact Sciences Corporation Financial Overview

Table 59        Sysmex Inostics Company Overview

Table 60        Sysmex Inostics Financial Overview

Table 61        Bio-Rad Laboratories Company Overview

Table 62        Bio-Rad Laboratories Financial Overview

Table 63        ANGLE plc Company Overview

Table 64        ANGLE plc Financial Overview